pre-IPO PHARMA

COMPANY OVERVIEW

Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines. Our goal is to revolutionize gene editing for the benefit of patients around the world.


LOCATION


THERAPEUTIC AREAS


WEBSITE

None


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


May 19, 2023

Metagenomi Presents New Data on Novel Gene Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting


May 2, 2023

Metagenomi to Present New Data for Its Novel Gene-Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting


Mar 6, 2023

Metagenomi Announces Participation in March Investor Conferences


Mar 2, 2023

Metagenomi Recognized as One of World’s Most Innovative Companies by Fast Company


Feb 14, 2023

Metagenomi Appoints Sarah Noonberg, M.D., Ph.D. as Chief Medical Officer


For More Press Releases


Google Analytics Alternative